Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.
Understand this study
What is this study about?
Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 20 years to 66 years. Other eligibility criteria apply.
- Listed locations
- Chino and 50 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 268
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Russia
- Age range
- From 20 Years to 66 Years
- Official registry ID
- NCT01834638
- Official title
Show the full official title
Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855
Recruitment & locations
Chino, United States · Costa Mesa, United States · Escondido, United States
38 more locations
- Garden Grove, United States
- National City, United States
- Norwalk, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Bernardino, United States
- San Diego, United States
- San Gabriel, United States
- Santa Ana, United States
- Torrance, United States
- New Haven, United States
- Atlanta, United States
- Marietta, United States
- Chicago, United States
- Hoffman Estates, United States
- Cedarhurst, United States
- Rochester, United States
- Philadelphia, United States
- DeSoto, United States
- Houston, United States
- Chita, Russia
- Kazan', Russia
- Lipetsk, Russia
- Moscow, Russia
- Novosibirsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Stavropol, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Edinburgh, United Kingdom
- London, United Kingdom
- Newcastle upon Tyne, United Kingdom
- Oxford, United Kingdom
- Russia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.
Who is behind this study?
The study sponsor is AbbVie.
Does this study involve medication?
Yes. The study involves medication, including ABT-126.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 20 years to 66 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
